BioVie, a Phase 2 biotech developing therapies for cirrhosis, raised $16 million by offering 1.6 million shares at $10, below the last close of its shares on the OTC (BIVI). The company offered 0.3 million more shares than anticipated.
BioVie plans to list on the Nasdaq under the symbol BIVI. ThinkEquity and Kingswood Capital Markets acted as lead managers on the deal.
